Enodia Therapeutics Appoints Henrik Torp Nielsen as Chief Financial Officer to Support Corporate Growth and Strategic Development

Experienced finance leader brings deep expertise in biotech financing, strategic transactions and organizational scaling

PARIS – Oct. 29, 2026 – Enodia Therapeutics, a biotechnology company developing small-molecule therapies targeting a unique form of protein degradation at the point of synthesis, appointed Henrik Torp Nielsen as Chief Financial Officer. With nearly two decades of experience in biopharma finance and operations, Mr. Nielsen will lead Enodia's financial strategy and operations as the company advances its proprietary Sec61 platform. Enodia's approach selectively degrades disease-driving proteins before they mature and exert pathological effects, with an initial focus on inflammatory and autoimmune diseases and additional opportunities in oncology.



"Henrik joins Enodia at an important stage in our evolution as we continue to build our organization and advance our differentiated Sec61 platform toward key development milestones," said Yves Ribeill, Chief Executive Officer of Enodia Therapeutics. "His broad experience across biotechnology and global pharmaceutical companies, combined with his expertise in corporate finance, business development and organizational growth, will be instrumental as we continue to build Enodia for long-term success."

Prior to joining Enodia, Mr. Nielsen served as Head of Finance of Azafaros AG, where he led the company's financial strategy and helped secure €132 million through convertible debt and Series B financing. Prior to Azafaros, Mr. Nielsen spent more than 15 years at Novartis in senior finance leadership roles spanning oncology, business development, commercial operations, and global manufacturing. He has extensive experience supporting company growth, strategic transactions, investor relations, and organizational scaling across global markets. Mr. Nielsen holds an MBA and Master of Science degree in Economics and Business Administration from Copenhagen Business School.

“I am excited to join Enodia at this pivotal time,” said Henrik. “Enodia has built a differentiated platform with the potential to address significant unmet needs. I look forward to helping the company execute its growth strategy, strengthen its financial and operational foundation, and position the organization to achieve its next stage of development while advancing innovative therapies for patients.”

About Enodia Therapeutics
Enodia Therapeutics is a biotechnology company focused on developing best-in-class small-molecule therapies that enable the degradation of disease-driving proteins at the point of synthesis, before they have a damaging effect. Rooted in pioneering research from the Institut Pasteur and built by Argobio, Enodia, through its Sec61 platform, is advancing a pipeline initially focused on inflammation, immunology and oncology, with additional opportunities in virology. For additional information please visit: enodiatx.com.

Media Contact
Susan Sharpe
Linnden Communications
susan@linndencom.com

Company Contact
Morgane Schwenzer
morgane.schwenzer@enodiatx.com